Used in immunotherapy research to modulate T-cell activity by blocking the LAG3 receptor, which plays a role in immune checkpoint pathways. This antibody serves as a reference standard in the development of anti-LAG3 therapeutics, aiding in the characterization and validation of drug candidates targeting immune exhaustion in cancer. It supports assay development, binding studies, and bioactivity testing in preclinical models. Its well-defined properties make it valuable for benchmarking new LAG3-targeting antibodies in oncology and autoimmune disease research.